Leerink Partnrs Comments on ACADIA Pharmaceuticals Inc.'s Q3 2023 Earnings (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Research analysts at Leerink Partnrs reduced their Q3 2023 earnings per share estimates for shares of ACADIA Pharmaceuticals in a report released on Wednesday, August 2nd. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of ($0.41) for the quarter, […]

Related Keywords

James Kihara ,Leerink Partnrs ,Laura Brege ,Vanguard Group Inc ,Blackrock Inc ,Canaccord Genuity Group ,Pharmaceuticals Daily ,Nasdaq ,Pharmaceuticals Price Performance ,Acadia Pharmaceuticals Inc ,Pharmaceuticals Inc ,Morgan Stanley ,Pricet Rowe Associates Inc ,Cantor Fitzgerald ,Securities Exchange Commission ,Free Report ,Genuity Group ,Get Free Report ,Exchange Commission ,Director Laura Brege ,Street Corp ,Pricet Rowe Associates ,Acadia Pharmaceuticals ,Nasdaq Acad ,Facad ,Medical ,Earnings Estimates ,